

# Diona Damian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3763537/publications.pdf>

Version: 2024-02-01

41  
papers

2,183  
citations

279798

23  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1942  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. <i>New England Journal of Medicine</i> , 2015, 373, 1618-1626.	27.0	469
2	UV Radiation-Induced Immunosuppression Is Greater in Men and Prevented by Topical Nicotinamide. <i>Journal of Investigative Dermatology</i> , 2008, 128, 447-454.	0.7	167
3	Positron emission tomography in the detection and management of metastatic melanoma. <i>Melanoma Research</i> , 1996, 6, 325-330.	1.2	164
4	Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. <i>Carcinogenesis</i> , 2008, 30, 101-105.	2.8	109
5	Nicotinamide Prevents Ultraviolet Radiation-Induced Cellular Energy Loss. <i>Photochemistry and Photobiology</i> , 2010, 86, 942-948.	2.5	102
6	Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin. <i>Carcinogenesis</i> , 2013, 34, 1144-1149.	2.8	98
7	An action spectrum for ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.5	90
8	A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. <i>British Journal of Dermatology</i> , 2016, 175, 1073-1075.	1.5	88
9	Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. <i>British Journal of Dermatology</i> , 2009, 161, 1357-1364.	1.5	75
10	Measurement of ultraviolet radiation-induced suppression of recall contact and delayed-type hypersensitivity in humans. <i>Methods</i> , 2002, 28, 34-45.	3.8	66
11	Topical calcitriol protects from UV-induced genetic damage but suppresses cutaneous immunity in humans. <i>Experimental Dermatology</i> , 2010, 19, e23-30.	2.9	66
12	Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 308-313.	1.7	63
13	Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. <i>Experimental Dermatology</i> , 2019, 28, 15-22.	2.9	63
14	Demodex infestation in a child with leukaemia: treatment with ivermectin and permethrin. <i>International Journal of Dermatology</i> , 2003, 42, 724-726.	1.0	58
15	Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2009, 50, 266-271.	0.7	48
16	Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. <i>Experimental Dermatology</i> , 2014, 23, 509-511.	2.9	44
17	Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 869-871.	1.2	40
18	Nicotinamide Enhances Repair of Arsenic and Ultraviolet Radiation-Induced DNA Damage in HaCaT Keratinocytes and Ex Vivo Human Skin. <i>PLoS ONE</i> , 2015, 10, e0117491.	2.5	38

#	ARTICLE	IF	CITATIONS
19	Measurement of In Vivo Sunscreen Immune Protection Factors in Humans. <i>Photochemistry and Photobiology</i> , 1999, 70, 910-915.	2.5	35
20	Nicotinamide for Skin-Cancer Chemoprevention. <i>New England Journal of Medicine</i> , 2016, 374, 789-790.	27.0	35
21	Photoprotective effects of nicotinamide. <i>Photochemical and Photobiological Sciences</i> , 2010, 9, 578-585.	2.9	33
22	Effects of low-dose ultraviolet radiation on in vivo human cutaneous recall responses. <i>Australasian Journal of Dermatology</i> , 2001, 42, 161-167.	0.7	28
23	Sun protection factor measurement of sunscreens is dependent on minimal erythema dose. <i>British Journal of Dermatology</i> , 1999, 141, 502-507.	1.5	27
24	Nicotinamide for skin cancer chemoprevention. <i>Australasian Journal of Dermatology</i> , 2017, 58, 174-180.	0.7	24
25	Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo. <i>Photochemical and Photobiological Sciences</i> , 2020, 19, 171-179.	2.9	24
26	Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2018, 34, 5-12.	1.5	22
27	Treatment of Refractory Chromomycosis by Isolated Limb Infusion with Melphalan and Actinomycin D. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, 48-51.	1.2	20
28	A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide. <i>Journal of Investigative Dermatology</i> , 2019, 139, 467-469.	0.7	17
29	Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2016, 175, 1363-1365.	1.5	16
30	Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting. <i>Pathology</i> , 2016, 48, 395-397.	0.6	15
31	Topical riboflavin attenuates ultraviolet B- and ultraviolet A-induced immunosuppression in humans. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2010, 26, 66-69.	1.5	8
32	Dramatic regression of cutaneous, nodal, and visceral melanoma metastases. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 665-666.	1.2	7
33	Measurement of In Vivo Sunscreen Immune Protection Factors in Humans. <i>Photochemistry and Photobiology</i> , 1999, 70, 910.	2.5	7
34	A Plethora of Protein. <i>American Journal of Medicine</i> , 2010, 123, 904-906.	1.5	3
35	Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide. <i>Geriatrics (Switzerland)</i> , 2019, 4, 31.	1.7	3
36	The Topical Isoflavonoid Naringenin Reduces Solar-Simulated UVB-Induced Suppression of Mantoux Reactions in Humans. <i>Photochemistry and Photobiology</i> , 2004, 80, 416-421.	2.5	2

#	ARTICLE	IF	CITATIONS
37	Authors' response to a reply to "A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients"™. <i>British Journal of Dermatology</i> , 2017, 176, 552-553.	1.5	2
38	Interventions to Increase Sunscreen Use in Adults: A Review of the Literature. <i>Health Education and Behavior</i> , 2022, 49, 415-423.	2.5	2
39	Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor. <i>Skin Health and Disease</i> , 0, , e71.	1.5	2
40	Prediction of minimal erythema dose with a reflectance melanin meter. <i>British Journal of Dermatology</i> , 1997, 136, 714-8.	1.5	2
41	Measurement of in vivo sunscreen immune protection factors in humans. <i>Photochemistry and Photobiology</i> , 1999, 70, 910-5.	2.5	1